Pharmaceutical composition comprising padina arborescens extract as active ingredient for inhibiting LRRK2 kinase activity or for Anti-neuroinflammation
The Buchatmal extract addresses the toxicity issues of existing LRRK2 inhibitors by effectively inhibiting LRRK2 kinase activity and reducing neuroinflammation, offering a stable treatment for degenerative brain diseases.
WO2025216370A1 Publication Date: 2025-10-16WONKWANG UNIV CENT FOR IND ACAD COOP
5 Cites 0 Cited by
Patent Information
- Application Number
- PCT/KR2024/014783
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-12
- Filing Date
- 2024-09-27
- Publication Date
- 2025-10-16
AI Technical Summary
Technical Problem
Existing LRRK2 inhibitors face issues of unexpected toxicity in clinical trials and induce oxidative stress and neuroinflammation, while natural compounds like Buchatmal's potential to inhibit LRRK2 kinase activity and neuroinflammation remain unexplored.
Method used
A pharmaceutical composition containing an extract of Buchatmal, which suppresses LRRK2 phosphorylation enzyme activity, reduces inflammatory cytokines, and has antioxidant effects, formulated into various forms for oral and external use.
Benefits of technology
The Buchatmal extract effectively inhibits LRRK2 kinase activity, reduces neuroinflammation, and has fewer side effects compared to artificial compounds, providing a stable treatment for degenerative brain diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a pharmaceutical composition for inhibiting the activity of leucine-rich repeat kinase 2 (LRRK2) or for anti-neuroinflammation, and more specifically, to a pharmaceutical composition comprising a Padina arborescens extract as an active ingredient for inhibiting the activity of leucine-rich repeat kinase 2 (LRRK2) or for anti-neuroinflammation. According to the present invention, the risk of developing diseases and neuroinflammation due to the activity of the LRRK2 kinase is reduced, and the LRRK2 kinase can be utilized in medicines, foods, quasi-drugs, etc. for preventing, alleviating, and treating diseases and neuroinflammation due to the activity of the LRRK2 kinase.
Need to check novelty before this filing date? Find Prior Art